Publikationen 2008

Publikationen 2008
Journalbeitrag
1. Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, von Minckwitz G, Thomssen
C, Harbeck N (2008) uPA and PAI-1 in breast cancer: review of their clinical utility and current
validation in the prospective NNBC-3 trial. ADV CLIN CHEM, 45: 31-45
2. Bartel F, Jung J, Böhnke A, Gradhand E, Zeng K, Thomssen C, Hauptmann S (2008) Both
germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and
survival. CLIN CANCER RES, 14(1): 89-96
3. Bartel G, Jung J, Böhnke A, Gradhand E, Zeng K, Thomssen C, Hauptmann C (2008) Both
germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and
survival. CLIN CANCER RES, 1: 89-96
4. Dittmer A, Dittmer J, Schunke D, Thomssen C (2008) TGFR and ERK1/2 pathway regulate
homotypic breast cancer cell aggregation. ONKOLOGIE, 21: 154
5. Dittmer A, Schunke D, Dittmer J (2008) PTHrP promotes homotypic aggregation of breast
cancer cells in three-dimensional cultures. CANCER LETT, 260(1-2): 56-61
6. Dittmer J (2008) Novel Roles of Ets1 in Cancer Progression. ANTICANCER RES, 28: 3264
7. Dittmer J, Schunke D, Span P, Ronneburg H, Vetter M, Holzhausen HJ, Kantelhardt EJ,
Mueller V, Sweep F, Thomssen C (2008) Cox-2 is a target gene of Rho GDP dissociation
inhibior beta in breast cancer cells. FEBS J, 1: 331
8. Goepel C (2008) Differential elastin and tenascin immunolabeling in the uterosacral ligaments
in postmenopausal women with and without pelvic organ prolapse. ACTA HISTOCHEM, 110:
204-209
9. Göpel C, Störer S, Kantelhardt E (2008) Collagen matrix mesh implants (Veritas) in the
surgical therapy of cystocele. Gynäkol Geburtshilfliche Rundsch, 48(1): 31-34
10. Göpel C, Störer S, Kantelhardt E (2008) Kollagen-Matrix-Implantate in der operativen
Therapie der Zystozele. Gynäkol Geburtshilfliche Rundsch, 48: 31-34
11. Harbeck N, Kates R, Thomssen C, Jänicke F, Schmitt M (2008) Challenging tumour
aggressiveness - Individualising patient management. EJC SUPPL, 6: 2-3
12. Harbeck N, Jakesz R, Thomssen C (2008) The Future of Breast Cancer Management.
BREAST CARE, 3 (6): 381-382
13. Harbeck N, Schmitt M, Vetter M, Krol J, Paepke D, Uhlig M, Paepke S, Jänicke F, GeutsMoespot A, von Minckwitz G, Sweep F, Thomssen C (2008) Prospektive Biomarker Trials
Chemo N0 and NNBC-3Europe Validate the clinical Utility of Invasion Markers uPA and PAI-1
in Node-Negative Breast Cancer. BREAST CARE, 3: 11-15
14. Harbeck N, Thomssen C (2008) Perception of ASCO 2008. BREAST CARE, 3 (4): 279-282
15. Jackisch C, Untch M, Chatsiproios D, Lamparter C, Overkamp F, Lichtenegger W, Rnsberg
W, Thomssen C, von minckwitz G, Albert US (2008) Adherence to Treatment Guidelines in
Breast Cancer Care - a retrospective Analysis of the Organsgruppe Mamma der AGO.
BREAST CARE, 3: 87-92
16. Kantelhardt E, Große R, Strauß HG, Thomssen C (2008) Mammakarzinom - State of the Art
2008. Ärztewoche, 39: 4
17. Kantelhardt E, Große R, Strauß HG, Thomssen C (2008) Mammakarzinom - State of the Art
2008. Der Gynäkologe, 9: 672-682
18. Kantelhardt E, Hanson C, Albert UA, Wacker J (2008) Breast Cancer in countries of Limited
Resources. BREAST CARE, 3: 10-16
19. Kantelhardt EJ, Kübler KC, Strauß HG, Thomssen C (2008) Presentation, therapy and course
of the diesease of 58 patients with cerebral metastasis from breast cancer at the department
of gynaecology of the University Halle/Saale. ONCOLOGIST, 31: 153-154
20. Kantelhardt EJ, Pauli N, Vetter M, Große R, Strauß HG, Thomssen C (2008) Evaluation of
pre-operative cancer marker CA 15-3 and CEA in breast cancer (n= 1093) patient population
(1998-2006) Department for gynecology. GEBURTSH FRAUENHEILK, 68: 59-60
21. Kantelhardt EJ, Thomssen C (2008) The current recommendations of the AGO commission
Mamma. GEBURTSH FRAUENHEILK, 68: 96-100
22. Kantelhardt EJ, Vetter M, Thomssen C (2008) Sekundäres Mammakarzinom - State of the Art.
Pharma Focus Gynäkologie, 1: 22-26
23. Kantelhardt E, Pauli N, Vetter M, Grosse R, Dittmer J, Strauss HG, Thomssen C (2008) Reevaluation of the old preoperative prognostic markers CA15-3 and CEA using a cohort of 1093
patients treated for breast cancer 1998-2006 at a single institution. EJC SUPPL, 6: 189
24. Kantelhardt E, Thomssen C (2008) Die aktuellen Empfehlungen der AGO Kommission
Mamma. Senologie, 5: 18-23
25. Kantelhardt E, Thomssen C (2008) Die aktuellen Empfehlungen der AGO Kommission
Mamma. GEBURTSH FRAUENHEILK, 1: 96-100
26. Kantelhardt E, Thomssen C (2008) Diagnostik und Therapie des Mammakarzinoms.
Orthopädietechnik, 9: 674-679
27. Kantelhardt EJ, Große R, Strauß HG (2008) Diagnostik und Therapie des Mammakarzinoms.
Tumrodiagn u ther, 29: 23-26
28. Kantelhardt EJ, Thomssen C (2008) German Recommendations for Diagnosis and Treatment
of Breast Cancer 2008. What ist New from the Breast Comission of the German
Gynaecological Oncology Working Group (AGO)? BREAST CARE, 3: 93-99
29. Keyver-Paik MD, Polcher M, Malcher S, Ortmann O, Hilfrich J, Diedrich K, Breitbach P, Hoss
C, Möbus V, Thomssen C, Kuhn W (2008) Response evaluation of neoadjuvant
chemotherapy in advanced ovarian cancer patients (prospective, randomized phase II clinical
trial to select primary chemotherapy with carboplatin and docetaxel in patients with advanced
ovarian cancer stage FIGO IIC and IV Primovar. ONKOLOGIE, 31: 109
30. Meyer J, Strauß HG, Thomssen C (2008) Systematic therapy of a paracaval late relapse
during low grade endometrial stromal tumor celss- A case presentation. GEBURTSH
FRAUENHEILK, 68: 108
31. Richter F, Karbe I, Strauß HG, Thomssen C (2008) Ovarian Carcinoma FIGO III and IV result
of University Gynecology Clinic observation period from 2004 untill 2007. GEBURTSH
FRAUENHEILK, 68: 67
32. Schmidt M, Victor A, Bohm D, Lebrecht A, Siggelkow W, Lehi HA, Koelbl H, von Minckwitz G,
Harbeck N, Thomssen C (2008) Long-term prognostic impact of risk classifications in nodenegative breast cancer - comparison between adjuvant, St. Gallen and a novel risk algorithm
used in the prospectively randomized Node-Negative-Breast-Cancer-3 trial. EJC SUPPL, 6:
194
33. Schrohl AS, Mueller V, Christensen IJ, Pantel K, Thomssen C, Bruenner N (2008) A
comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour
tissue from patients with primary breast cancer and in plasma from patients with metastatic
breast cancer. TUMOR BIOL, 29(3): 181-7
34. Schrohl AS, Mueller V, Christensen IJ, Pantel K, Thomssen C, Bruenner N (2008) A
comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour
tissue from patiens with primary breast cancer and in plasma from patients with metastatic
breast cancer. TUMOR BIOL, 29 (3): 181-187
35. Schunke D, Span P, Ronneburg H, Dittmer A, Vetter M, Holzhausen HJ, Kantelhardt EJ,
Mueller V, Sweep F, Thomssen C, Dittmer J (2008) Cox -1 is a target gene of Rho GDP
dissociation inhibitor beta in breast cancer cells. INT J MOL MED, 1: 51
36. Schunke D, Span P, Ronneburg H, Dittmer A, Vetter M, Holzhausen HJ, KantelhardtqEJ EJ,
Mueller V, Sweep F, Thomssen C, Dittmer J (2008) Cox-2 is a target gene of Rho GDP
dissociation inhibitor beta in breast cancer cells. EJC SUPPL, 6: 82
37. Seliger G, Müller LP, Kegel T, Kantelhardt EJ, Grothey A, Große R, Strauß HG, Kölbl H,
Thomssen C, Schmoll HJ (2008) Phase IItrial of docetaxel, gemcitabine and oxaliplatin
combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
International Journal of gynecological Cancer, 1: 1-10
38. Stang A, Thomssen C (2008) Decline in breast cancer incidence in the United States: what
about male breast cancer? BREAST CANCER RES TR, 112(3): 595-6
39. Strauss HG, Hemsen A, Karbe I, Lautenschläger C, Persing M, Thomssen C (2008) Phase II
trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and
peritoneal cancer. ANTI-CANCER DRUG, 19(5): 541-5
40. Thomssen C (2008) Perspectives on Breast Cancer Management: Tailoring Treatment to the
Individual Patient. BREAST CARE, 3: 21-23
41. Thomssen C (2008) Maßgeschneiderte Therapie beim Mammakarzinom. GynSpectrum, 3: 36
42. Thomssen C (2008) Therapie und Forschung des Gebärmutterhalskrebses. Krebsmagazin,
20: 28-30
43. Thomssen C (2008) AGO-Empfehlungen Mammakarzinom Diagnostik und Therapie - Update
2008. Gynäkologie und Geburtshilfe, 2: 38-40
44. Thomssen C, Huober J (2008) Primäre und adjuvante Systemtherapie des operablen
Mammakarzinoms. ONKOLOGE, 5: 504-513
45. Thomssen C, Kantelhardt E, Vetter M (2008) Neue Wege der Risikovorhersage sowie
Ausblick auf die nächsten Jahre. Onkologie heute, 1: 14-18
46. Thomssen C, Kantelhardt E, Vetter M (2008) Neue Wege der Risikovorhersage sowie
Ausblick auf die nächsten Jahre. ONCOLOGIST, 1: 14-18
47. Thomssen C, Vetter M (2008) Urokinase-type plasminogen activator (uPA) and its inhibitor
PAI-1 for tumor-biological risk assessment in note-negative breast cancer patients - The
multicenter trial NNBC3-Europe. EJC SUPPL, Band 6: 188
48. Trappe HJ, Thomssen C, Werdan K (2008) Internistische Erkrankungen in der
Schwangerschaft. Der Internist, 49 (7): 777-778
49. Vetter M, Geurts-Moespot A, Kantelhardt EJ, Sweep F, von Minckwitz G, Thomssen C,
Dittmer J, Harbeck N (2008) External and internal assurance of the determination of the
prognostic factors uPA and PAI-1 for the ongoing NNBC 3-Europe Trial. EJC SUPPL, 6: 192
50. von Minckwitz G, Eidtmann H, Groner B, Harbeck N, Huober J, Karn T, Komor M, Lenhardt M,
Loibl S, Martin B, Müller V, Niederacher D, Thomssen C, Kaufmann M (2008) Translational
Research for Breast Cancer - Workshop for new research ideas at the Biedenkopf Symposium
XIII of the Banss Foundation. GEBURTSH FRAUENHEILK, 68: 1160-1165
51. Wacker J, Zerm C, Mothes A, Kantelhardt EJ (2008) Behandlung der Komplikationen während
Schwangerschaft und Geburt bei Frauen nach Genitalbeschneidung. Der Gynäkologe, 9: 735743
Dissertation
1. Dittmer J (2008) Die Bedeutung der Ets-regulierten Proteine RhoGDiß und PTHrP für die
Biologie des invasiven Mammakarzinoms. Dissertation Universität Halle
Buchbeitrag
1. Dittmer J (2008) Parathyroid Hormone-related Protein. In: M. Schwab (Hg.) Encyclopedia of
Cancer. Springer Verlag, München, 2262-2264
2. Dittmer J (2008) Ets transcription factors. In: Springer Verlag (Hg.) Encyclopedia of Cancer.
Springer Verlag, München, 1061-1063
3. Kantelhardt EJ, Vetter M, Harbeck N, Thomssen C (2008) Praxisrelevante und
evidenzbasierte prognostische und prädiktive Faktoren beim Mammakarzinom. In: Untch und
Sittek (Hg.) Diagnostik und Therapie des Mammakarzinoms, State of the Art. Zuckschwerdt
München, München, 228-239
4. Strauß HG, Thomssen C (2008) Gynäkologische Tumoren. In: Urban und Fischer (Hg.)
Therapiehandbuch. Urban und Fischer, München-Jena, 1-20